SEC Form 4 · accession 0001209191-18-042903

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, CRO

Period of report

Jul 13, 2018

Accepted (ET)

Jul 17, 2018 · 6:30 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jul 13, 2018	M	12,031	$96.87	A	58,693	D
Common Stock	Jul 13, 2018	S	12,031	$180.00	D	46,662	D
Common Stock	Jul 16, 2018	M	1,719	$96.87	A	48,381	D
Common Stock^F2,F3	Jul 16, 2018	S	1,500	$180.14	D	46,881	D
Common Stock^F3,F4	Jul 16, 2018	S	219	$181.88	D	46,662	D
Common Stock	holding	—	—		—	882	I	401(k)
Common Stock	holding	—	—		—	12,215	I	Held in Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F5	$96.87	Jul 13, 2018	M	12,031	D	—	Jul 14, 2024	Common Stock	12,031	1,719	D
Stock Option (Right to Buy)^F5	$96.87	Jul 16, 2018	M	1,719	D	—	Jul 14, 2024	Common Stock	1,719	0	D

F1Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $180.14 (range $180.00 - $180.66).
F3Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $181.88 (range $181.65 - $181.93).
F5Fully vested.